Regen Med. 2017 Jun 2. doi: 10.2217/rme-2017-0043. [Epub ahead of print]

Transplantation of allogeneic adipose-derived mesenchymal stem cells in a cerebral palsy patient.

Kantake M¹, Hirano A², Sano M³, Urushihata N⁴, Tanemura H⁴, Oki K⁴, Suzaki E⁴.

Abstract

We studied the safety and efficacy of allogeneic human adipose-derived mesenchymal cell (hAMSC) transplantation in a patient with cerebral palsy (CP). The patient received six infusions of allogeneic hAMSCs intravenously, without or with intramuscular or local injections and was followed up for 12 months. Changes in quality of life were assessed using the Short Form 8 health survey questionnaire incorporating physical and mental component summary scores. Clinical manifestations improved remarkably, with significant improvements in the quality of life physical and mental scores. No serious adverse effect or toxicity was observed. The patient maintained his recovery very well at 12 months follow-up. This case study suggests that allogeneic hAMSCs can be administered safely and feasibly in a pediatric patient with CP. Whether the results can be generalized to other pediatric patients with CP warrants further investigation.